Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First clinical study of a pegylated diabody 124I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers.
Scott AM, Akhurst T, Lee FT, Ciprotti M, Davis ID, Weickhardt AJ, Gan HK, Hicks RJ, Lee ST, Kocovski P, Guo N, Oh M, Mileshkin L, Williams S, Murphy D, Pathmaraj K, O'Keefe GJ, Gong SJ, Pedersen JS, Scott FE, Wheatcroft MP, Hudson PJ. Scott AM, et al. Among authors: guo n. Theranostics. 2020 Sep 15;10(25):11404-11415. doi: 10.7150/thno.49422. eCollection 2020. Theranostics. 2020. PMID: 33052222 Free PMC article. Clinical Trial.
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a.
Burvenich IJG, Parakh S, Lee FT, Guo N, Liu Z, Gan HK, Rigopoulos A, O'Keefe GJ, Gong SJ, Goh YW, Tochon-Danguy H, Scott FE, Kotsuma M, Hirotani K, Senaldi G, Scott AM. Burvenich IJG, et al. Among authors: guo n. Theranostics. 2018 Jul 30;8(15):4199-4209. doi: 10.7150/thno.25575. eCollection 2018. Theranostics. 2018. PMID: 30128047 Free PMC article.
Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.
Burvenich IJG, Goh YW, Guo N, Gan HK, Rigopoulos A, Cao D, Liu Z, Ackermann U, Wichmann CW, McDonald AF, Huynh N, O'Keefe GJ, Gong SJ, Scott FE, Li L, Geng W, Zutshi A, Lan Y, Scott AM. Burvenich IJG, et al. Among authors: guo n. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3075-3088. doi: 10.1007/s00259-021-05251-0. Epub 2021 Feb 19. Eur J Nucl Med Mol Imaging. 2021. PMID: 33608805
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls.
McMahon JH, Zerbato JM, Lau JSY, Lange JL, Roche M, Tumpach C, Dantanarayana A, Rhodes A, Chang J, Rasmussen TA, Mackenzie CA, Alt K, Hagenauer M, Roney J, O'Bryan J, Carey A, McIntyre R, Beech P, O'Keefe GJ, Wichmann CW, Scott FE, Guo N, Lee ST, Liu Z, Caskey M, Nussenzweig MC, Donnelly PS, Egan G, Hagemeyer CE, Scott AM, Lewin SR. McMahon JH, et al. Among authors: guo n. EBioMedicine. 2021 Mar;65:103252. doi: 10.1016/j.ebiom.2021.103252. Epub 2021 Feb 25. EBioMedicine. 2021. PMID: 33640794 Free PMC article. Clinical Trial.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM. Gan HK, et al. Among authors: guo n. Invest New Drugs. 2022 Aug;40(4):747-755. doi: 10.1007/s10637-022-01237-3. Epub 2022 Apr 11. Invest New Drugs. 2022. PMID: 35404015 Clinical Trial.
2,333 results